CYESTRA-35 TABLET

국가: 캐나다

언어: 영어

출처: Health Canada

유효 성분:

CYPROTERONE ACETATE; ETHINYL ESTRADIOL

제공처:

PALADIN LABS INC.

ATC 코드:

G03HB01

INN (국제 이름):

CYPROTERONE AND ESTROGEN

복용량:

2MG; 0.035MG

약제 형태:

TABLET

구성:

CYPROTERONE ACETATE 2MG; ETHINYL ESTRADIOL 0.035MG

관리 경로:

ORAL

패키지 단위:

21

처방전 유형:

Prescription

치료 영역:

OTHER MISCELLANEOUS THERAPEUTIC AGENTS

제품 요약:

Active ingredient group (AIG) number: 0232337001; AHFS:

승인 상태:

APPROVED

승인 날짜:

2007-03-01

제품 특성 요약

______________________________________________________________________________________________
_
_CYESTRA-35 Product Monograph Page 1 of 48 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
CYESTRA
®
-35
cyproterone acetate and ethinyl estradiol tablets
2 mg/0.035 mg
THERAPEUTIC CLASSIFICATION
Acne Therapy
Paladin Labs Inc.
Date of Preparation:
100 Alexis Nihon Blvd, Suite 600
January 17, 2019
St-Laurent, Quebec
Version: 6.0
H4M 2P2
Control # 223341
______________________________________________________________________________________________
_
_CYESTRA-35 Product Monograph Page 2 of 48 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..................................................................3
SUMMARY PRODUCT INFORMATION
......................................................................................3
INDICATION AND CLINICAL USE
..............................................................................................3
CONTRAINDICATIONS
...............................................................................................................3
WARNINGS AND PRECAUTIONS
...............................................................................................4
ADVERSE
REACTIONS..............................................................................................................
13
DRUG INTERACTIONS
..............................................................................................................
16
DOSAGE AND
ADMINISTRATION
.........................................................................................
20
OVERDOSAGE
...........................................................................................................................
22
ACTION AND CLINICAL PHARMACOLOGY
...........................................................................
22
STORAGE AND STABILITY
......................................................................................................
24
SPECIAL HANDLING INSTRUCTIONS
............................